



Topics: [Europe](#) | [Venture Capital](#)

Italy's Genenta Science raises \$11M for gene therapy program at TIGET

March 5, 2015 | By [John Carroll](#)

Milan-based Genenta Science has raised \$11 million for its work on a new gene therapy. According to a brief release, the biotech says that Banca Esperia, the private bank of Mediobanca and Mediolanum, supported the A round.



Genenta CEO Pierluigi Paracchi

The startup has had a low profile up to now. In a recent email to *FierceBiotech*, CEO Pierluigi Paracchi said that the biotech is working on a gene therapy to treat cancer tumors. They're working with Luigi Naldini, director of the San Raffaele-Telethon Institute for Gene Therapy, or TIGET. Paracchi has a background in biotech as a venture consultant at [Sofinnova Partners](#), which is based in Paris. He was a director at EOS, an Italian biotech that was acquired by Clovis Oncology ([\\$CLVS](#)) back in 2013 for \$420 million.

Bernhard Gentner, a hematologist and physician scientist at the San Raffaele Hospital, is listed as one of the co-founders of the company.

The Biotech Primer: An insider's guide to the science driving the biotech and pharma industries

This 200-page book takes an in-depth look at the biotech industry and the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come - and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends. [Click here](#) to buy today!

TIGET has had a growing presence in the hot gene therapy field. Just a few weeks ago Biogen Idec ([\\$BIIB](#)) and its newly named in-house expert Olivier Danos executed a research deal with TIGET to develop what they believe promises to be a durable gene therapy for hemophilia.

"The round was subscribed by private investors: entrepreneurs, managers, HNWI, family offices," Genenta noted in a statement. "The entrance of new shareholders allows Genenta Science to complete preclinical studies and to advance in the preparation of the clinical phase for its therapeutic protocols to treat tumors."

Part of the company's strategy revolves around targeted use of [interferon](#) directed straight at tumors, avoiding the toxicity issues that have limited interferon's usefulness as a therapy.

"We have spent several years researching novel strategies to treat tumors and now GENENTA Science aims to rapidly translate our laboratory results into clinical trials, paying most attention to scientific rigorousness and patient safety," says Naldini. "Our first clinical targets will be hematopoietic malignancies for which current therapies are unsatisfactory."

- here's the [release](#) (PDF)

JOIN 150,000+ INSIDERS
SIGN UP FOR OUR
NEWSLETTER

EMAIL ADDRESS

FierceBiotech is the drug development industry's news monitor, covering biopharma deals, clinical trials, FDA decisions, and more. Subscribe to our free daily email and join the largest, most influential biotechnology news audience in the world. Sign up today!

FierceBiotech

Join our network of over 270,000 readers in the life sciences industry

SIGN UP NOW!

THE LIBRARY: WEBINAR

Powering Product Development in Skin Care with Metabolic Profiling



| TUESDAY, MARCH 17TH | 11:30AM ET / 8:30AM PT | PRESENTED BY: METABOLON

Here we describe discovery approaches designed to broadly survey the skin metabolome as well as focused metabolomic assessment of sebum, stratum corneum, skin biopsy, cell culture and reconstructed skin models across a variety of conditions. Further, we share results from recent publications and practical clinical case studies. [Register today!](#)

[MORE ITEMS](#)

LATEST COMMENTARY

Surprised, stunned and supportive: Analysts assess AbbVie's \$21B Pharmacyclics deal

Introducing FierceBiotech's new podcast

Can Neil Woodford reignite the U.K.'s taste for biotech investments?

Is a weak Eli Lilly ripe for a takeover?

UPDATED: Merck KGaA carves into MS R&D after a string of setbacks

Related Articles:

Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia

Clovis bets up to \$420M on targeted cancer drug

SHARE



Email

28

Tweet

28

Tweet

Share

0

g+1

0

g+1

TOOLS



Comment



Print



Contact Author



Reprint

EVENTS

6th Proactive GCP Compliance Conference
March 24-25 — Philadelphia, PA

Bio-IT World Conference and Expo 2015
April 21-23 — Boston, MA

BioBasics: Biotech for the Non-Scientist
April 23-24 — Boston, MA — Sponsored by:
BioTech Primer

MORE EVENTS

FierceBiotech

Join our network of over 270,000 readers in the life sciences industry

SIGN UP NOW!

Filed Under [EuroBiotech Report](#), [interferon](#)

POPULAR STORIES

MOST READ

MOST SHARED

Surprised, stunned and supportive: Analysts assess AbbVie's \$21B Pharmacyclics deal

UPDATED: Novartis abandons its RNAi cast-offs from Alynlyam in \$35M fire sale to Arrowhead

Bristol-Myers bags a record-fast approval for its cancer blockbuster Opdivo

UPDATED: Bristol-Myers forges a billion-dollar cancer vaccine deal with Bavarian Nordic
UPDATED: Shire clearing out of Pennsylvania, joining industry migration to Boston-area hub

COMMENTS

PRESS RELEASES

[VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics\(R\) Technology](#)

[Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement](#)

[Philips and UC Irvine partner to develop standards for breast cancer screening](#)

[Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa™ Platform](#)

[Ironwood Pharmaceuticals Initiates Phase I Clinical Study of sGC Stimulator IW-1973](#)

[More Press Releases](#)

FEATURED JOBS

[Electronic Publishing Associate - Regulatory Affairs - Washington DC](#)

[Clinical Drug Supply Manager - Souderton, PA](#)

[Biomanufacturing Engineer - Billerica, MA](#)

[Senior Director, Product Marketing - Rheumatology, I&I Job - Warren, NJ](#)

[Senior Brand Analytics Manager - 849 - Deerfield](#)

[Need a job? Need to hire? Visit our jobs site.](#)

A publication of

FierceMarkets

FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 150,000 biotech industry leaders who subscribe to our free daily email. [Click here](#) to get your free weekly email briefing today!

The FierceMarkets Network:

Telecom

[FierceCable](#)
[FierceDeveloper](#)
[FierceWireless:Europe](#)
[FierceWirelessTech](#)
[FierceOnlineVideo](#)
[FierceTelecom](#)
[FierceWireless](#)

Marketing & Retail

[FierceCMO](#)
[FierceMobileMarketer](#)
[FierceRetail](#)
[FierceRetailIT](#)
[FierceMobileRetail](#)

Healthcare

[FierceEMR](#)
[FierceHealthcare](#)
[FierceHealthFinance](#)
[FierceHealthIT](#)
[FierceHealthPayer](#)
[FierceHealthPayerAntiFraud](#)
[FierceMobileHealthcare](#)
[FiercePracticeManagement](#)
[Hospital Impact](#)

Government

[FierceGovernment](#)
[FierceGovernmentIT](#)
[FierceHomelandSecurity](#)
[FierceMobileGovernment](#)
[FierceCities](#)
[FierceGovHealthIT](#)

Life Sciences

[FierceBiotechResearch](#)
[FierceBiotech](#)
[FierceBiotechIT](#)
[FierceCRO](#)
[FierceDiagnostics](#)
[FierceDrugDelivery](#)
[FierceMedicalDevices](#)
[FiercePharma](#)
[FiercePharmaAsia](#)
[FiercePharmaManufacturing](#)
[FiercePharmaMarketing](#)
[FierceVaccines](#)
[FierceAnimalHealth](#)

Enterprise IT

[FierceBigData](#)
[FierceCIO](#)
[FierceContentManagement](#)
[FierceDevOps](#)
[FierceEnterpriseCommunicatio](#)
[FierceITSecurity](#)
[FierceMobileIT](#)

Energy

[FierceEnergy](#)
[SmartGridNews](#)

Finance

[FierceCFO](#)
[FierceFinanceIT](#)

[Home](#) | [Subscribe](#) | [Manage Newsletter Subscriptions](#) | [Advertise](#) | [Contact](#) | [Mobile Apps](#) | [RSS](#) | [Privacy](#) | [Editors](#) | [List in Marketplace](#)

© 2015 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.